There is one clinical trial.
This is a prospective, observational study that will examine endothelial dysfunction in
atrial fibrillation before and after treatment with anti-arrhythmic agents and the extent to
which baseline endothelial dysfunction improves after treatment.
Whether missense mutation in Cyb5R3 T117S can predict atrial fibrillation recurrence.. null. --- T117S ---
Whether missense mutation in Cyb5R3 T117S is correlated with atrial fibrillation severity.. null. --- T117S ---
Primary Outcomes
Description: Change in microvascular endothelium dependent dilation (in response to acetylcholine) assessed with laser speckle contrast imaging after initiating antiarrhythmic medical therapy.
Measure: Change in microvascular endothelium dependent dilation following anti-arrhythmic therapy as measured in perfusion units
Time: 1 year
Secondary Outcomes
Measure: Correlation between microvascular endothelial dysfunction measured at baseline and atrial fibrillation recurrence. Time: 1 year
Measure: Correlation between microvascular endothelial function improvement with antiarrhythmic medications and atrial fibrillation recurrence. Time: 1 year
Measure: Correlation between microvascular endothelial function and atrial fibrillation severity represented by left atrial size and type of Afib (paroxysmal vs persistent). Time: 1 year
Measure: Change in other vasodilation dysfunction indices measured after initiating antiarrhythmic medical therapy. Time: 1 year
Measure: Correlation between vasodilation dysfunction indices measured at baseline and atrial fibrillation recurrence. Time: 1 year
Measure: Whether missense mutation in Cyb5R3 T117S can predict atrial fibrillation recurrence. Time: 1 year
Measure: Whether missense mutation in Cyb5R3 T117S is correlated with atrial fibrillation severity. Time: 1 year